Patents by Inventor Kunwar Shailubhai

Kunwar Shailubhai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
    Patent number: 9914752
    Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: March 13, 2018
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Kunwar Shailubhai, Gary S. Jacob
  • AGONISTS OF GUANYLATE CYCLASE AND THEIR USES
    Publication number: 20170349630
    Abstract: This invention provides novel guanylate cyclase C (GC-C) agonists and their therapeutic use. The agonists may be used either alone or in combination with one or more additional agents.
    Type: Application
    Filed: June 14, 2017
    Publication date: December 7, 2017
    Inventor: Kunwar SHAILUBHAI
  • Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
    Patent number: 9814752
    Abstract: This invention also provides a method to prevent, control, and treat a lipid metabolism disorder, a billary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodiesterases.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: November 14, 2017
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventor: Kunwar Shailubhai
  • AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS
    Publication number: 20170209531
    Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.
    Type: Application
    Filed: March 28, 2017
    Publication date: July 27, 2017
    Inventors: Kunwar SHAILUBHAI, Gary S. JACOB
  • FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE
    Publication number: 20170202903
    Abstract: The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Application
    Filed: March 23, 2017
    Publication date: July 20, 2017
    Inventors: Stephen COMISKEY, Rong FENG, John FOSS, Kunwar SHAILUBHAI
  • FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE
    Publication number: 20170202904
    Abstract: The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Application
    Filed: March 23, 2017
    Publication date: July 20, 2017
    Inventors: Stephen COMISKEY, Rong FENG, John FOSS, Kunwar SHAILUBHAI
  • Agonists of guanylate cyclase and their uses
    Patent number: 9708367
    Abstract: This invention provides novel guanylate cyclase C (GC-C) agonists and their therapeutic use. The agonists may be used either alone or in combination with one or more additional agents.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 18, 2017
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventor: Kunwar Shailubhai
  • AGONISTS OF GUANYLATE CYCLASE AND THEIR USES
    Publication number: 20170143789
    Abstract: This invention provides a method of colonic cleansing.
    Type: Application
    Filed: December 16, 2016
    Publication date: May 25, 2017
    Inventors: Dennis RIFF, Gary S. JACOB, Kunwar SHAILUBHAI, Patrick H. GRIFFIN
  • PROCESS OF PREPARING GUANYLATE CYCLASE C AGONISYS
    Publication number: 20170129925
    Abstract: The invention provides processes of preparing a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-249 described herein.
    Type: Application
    Filed: January 13, 2017
    Publication date: May 11, 2017
    Applicant: Synergy Pharmaceuticals Inc.
    Inventors: Juncai Bai, Ruoping Zhang, Jun Jian, Junfeng Zhou, Qiao Zhao, Guoquing Zhang, Kunwar Shailubhai, Stephen Comiskey, Rong Feng
  • Formulations of guanylate cyclase C agonists and methods of use
    Patent number: 9616097
    Abstract: The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Grant
    Filed: March 15, 2012
    Date of Patent: April 11, 2017
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Stephen Comiskey, Rong Feng, John Foss, Kunwar Shailubhai
  • Formulations of guanylate cyclase C agonists and methods of use
    Patent number: 9610321
    Abstract: The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: April 4, 2017
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Stephen Comiskey, Rong Feng, John Foss, Kunwar Shailubhai
  • Process of preparing guanylate cyclase C agonists
    Patent number: 9580471
    Abstract: The invention provides processes of preparing a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-249 described herein.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: February 28, 2017
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoquing Zhang, Kunwar Shailubhai, Stephen Comiskey, Rong Feng
  • AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS
    Publication number: 20170029468
    Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.
    Type: Application
    Filed: October 19, 2016
    Publication date: February 2, 2017
    Inventor: Kunwar SHAILUBHAI
  • Agonists of guanylate cyclase and their uses
    Patent number: 9545446
    Abstract: This invention provides a method of colonic cleansing.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: January 17, 2017
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Dennis Riff, Gary S. Jacob, Kunwar Shailubhai, Patrick H. Griffin
  • COMPOSITIONS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
    Publication number: 20170000843
    Abstract: This invention provides novel peptides and methods to prevent, control, and treat an inflammation, cancer and other disorders, particularly of the gastrointestinal tract and the lung by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound selected from i) 5-aminosalicyclic acid (5-ASA) or a derivative or a pharmaceutically acceptable salt thereof; ii) mercaptopurine; or iii) an anti-TNF therapy.
    Type: Application
    Filed: September 22, 2016
    Publication date: January 5, 2017
    Inventor: Kunwar SHAILUBHAI
  • AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF OPIOID INDUCED DYSFUNCTIONS
    Publication number: 20160367622
    Abstract: This invention provides a method to prevent, control, and/or treat opioid induced dysfunctions comprising administering to a patient in need a guanylate cyclase receptor agonist (GCRA) peptide. Compositions comprising guanylate cyclase receptor agonist (GCRA) peptides, methods of making, and methods of treatment are also disclosed.
    Type: Application
    Filed: November 18, 2015
    Publication date: December 22, 2016
    Inventors: Kunwar SHAILUBHAI, Vaseem PALEJWALA
  • AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS
    Publication number: 20160367623
    Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer), a lipid metabolism disorder, a billary disorder, cardiovascular disease, obesity or an endocrine disorder) by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodiesterases.
    Type: Application
    Filed: June 16, 2016
    Publication date: December 22, 2016
    Inventor: Kunwar SHAILUBHAI
  • Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
    Patent number: 9505805
    Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: November 29, 2016
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventor: Kunwar Shailubhai
  • AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS
    Publication number: 20160340390
    Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.
    Type: Application
    Filed: December 9, 2015
    Publication date: November 24, 2016
    Inventors: Kunwar SHAILUBHAI, Gary S. JACOB
  • Compositions useful for the treatment of gastrointestinal disorders
    Patent number: 9486494
    Abstract: This invention provides novel peptides and methods to prevent, control, and treat an inflammation, cancer and other disorders, particularly of the gastrointestinal tract and the lung by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound selected from i) 5-aminosalicyclic acid (5-ASA) or a derivative or a pharmaceutically acceptable salt thereof; ii) mercaptopurine; or iii) an anti-TNF therapy.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: November 8, 2016
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventor: Kunwar Shailubhai